Cargando…

Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment

Background: The impact of the COVID-19 pandemic on the mental health of patients suffering from addictive disorders is of major concern. This study aimed to explore the presence and potential increase in post-traumatic stress disorder (PTSD) symptoms, depression, and anxiety since the beginning of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs-Leitner, Isabella, Yazdi, Kurosch, Gerstgrasser, Nikolas W., Tholen, Matthias G., Graffius, Sophie-Therés, Schorb, Alexander, Rosenleitner, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514667/
https://www.ncbi.nlm.nih.gov/pubmed/34658964
http://dx.doi.org/10.3389/fpsyt.2021.729460
_version_ 1784583442850119680
author Fuchs-Leitner, Isabella
Yazdi, Kurosch
Gerstgrasser, Nikolas W.
Tholen, Matthias G.
Graffius, Sophie-Therés
Schorb, Alexander
Rosenleitner, Jan
author_facet Fuchs-Leitner, Isabella
Yazdi, Kurosch
Gerstgrasser, Nikolas W.
Tholen, Matthias G.
Graffius, Sophie-Therés
Schorb, Alexander
Rosenleitner, Jan
author_sort Fuchs-Leitner, Isabella
collection PubMed
description Background: The impact of the COVID-19 pandemic on the mental health of patients suffering from addictive disorders is of major concern. This study aimed to explore the presence and potential increase in post-traumatic stress disorder (PTSD) symptoms, depression, and anxiety since the beginning of the pandemic for patients in opioid substitution therapy (OST). Methods: This cross-sectional survey study evaluated a clinical sample of patients in OST (N = 123). Symptoms of post-traumatic stress disorder (PTSD) due to the COVID-19 pandemic were assessed by an adapted version of the impact of event scale (IES-R), resulting in two subgroups of low and high risk for PTSD. The depression, anxiety, and stress scale (DASS-21) was applied to collect data on the respective symptoms, and changes since the onset of the pandemic were reported on separate scales. Sociodemographic and COVID-19 related factors, as well as data on craving, consumption patterns, concomitant use, and the drug market were further assessed. Results: A binary logistic regression analysis confirmed the impact of self-perceived higher burden by psychological and economic factors on the elevated risk for PTSD due to the pandemic. The high-risk PTSD group also showed higher levels of depression, anxiety and stress, as well as a more pronounced deterioration in these symptoms since the pandemic. While reported levels of craving did not differ between the two groups, the high-risk PTSD group indicated a significantly higher increase in craving since the crisis, when compared to the low-risk group. Discussion: Our findings demonstrate elevated levels of clinical symptoms among patients in OST, with more than a quarter of patients found at risk for PTSD due to the COVID-19 pandemic. Furthermore, about 30–50% of our patients reported concerning levels of depression, anxiety, or stress. Special attention should be drawn to these findings, and potential deterioration of the situation should be addressed by health care facilities. Particularly, psychological, and financial burden due to the crisis were identified as factors increasing the risk for PTSD. These factors can easily be evaluated during routine anamneses, and might be a valuable source of information, when special attention is needed.
format Online
Article
Text
id pubmed-8514667
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85146672021-10-15 Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment Fuchs-Leitner, Isabella Yazdi, Kurosch Gerstgrasser, Nikolas W. Tholen, Matthias G. Graffius, Sophie-Therés Schorb, Alexander Rosenleitner, Jan Front Psychiatry Psychiatry Background: The impact of the COVID-19 pandemic on the mental health of patients suffering from addictive disorders is of major concern. This study aimed to explore the presence and potential increase in post-traumatic stress disorder (PTSD) symptoms, depression, and anxiety since the beginning of the pandemic for patients in opioid substitution therapy (OST). Methods: This cross-sectional survey study evaluated a clinical sample of patients in OST (N = 123). Symptoms of post-traumatic stress disorder (PTSD) due to the COVID-19 pandemic were assessed by an adapted version of the impact of event scale (IES-R), resulting in two subgroups of low and high risk for PTSD. The depression, anxiety, and stress scale (DASS-21) was applied to collect data on the respective symptoms, and changes since the onset of the pandemic were reported on separate scales. Sociodemographic and COVID-19 related factors, as well as data on craving, consumption patterns, concomitant use, and the drug market were further assessed. Results: A binary logistic regression analysis confirmed the impact of self-perceived higher burden by psychological and economic factors on the elevated risk for PTSD due to the pandemic. The high-risk PTSD group also showed higher levels of depression, anxiety and stress, as well as a more pronounced deterioration in these symptoms since the pandemic. While reported levels of craving did not differ between the two groups, the high-risk PTSD group indicated a significantly higher increase in craving since the crisis, when compared to the low-risk group. Discussion: Our findings demonstrate elevated levels of clinical symptoms among patients in OST, with more than a quarter of patients found at risk for PTSD due to the COVID-19 pandemic. Furthermore, about 30–50% of our patients reported concerning levels of depression, anxiety, or stress. Special attention should be drawn to these findings, and potential deterioration of the situation should be addressed by health care facilities. Particularly, psychological, and financial burden due to the crisis were identified as factors increasing the risk for PTSD. These factors can easily be evaluated during routine anamneses, and might be a valuable source of information, when special attention is needed. Frontiers Media S.A. 2021-09-30 /pmc/articles/PMC8514667/ /pubmed/34658964 http://dx.doi.org/10.3389/fpsyt.2021.729460 Text en Copyright © 2021 Fuchs-Leitner, Yazdi, Gerstgrasser, Tholen, Graffius, Schorb and Rosenleitner. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Fuchs-Leitner, Isabella
Yazdi, Kurosch
Gerstgrasser, Nikolas W.
Tholen, Matthias G.
Graffius, Sophie-Therés
Schorb, Alexander
Rosenleitner, Jan
Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
title Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
title_full Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
title_fullStr Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
title_full_unstemmed Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
title_short Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment
title_sort risk of ptsd due to the covid-19 pandemic among patients in opioid substitution treatment
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514667/
https://www.ncbi.nlm.nih.gov/pubmed/34658964
http://dx.doi.org/10.3389/fpsyt.2021.729460
work_keys_str_mv AT fuchsleitnerisabella riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment
AT yazdikurosch riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment
AT gerstgrassernikolasw riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment
AT tholenmatthiasg riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment
AT graffiussophietheres riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment
AT schorbalexander riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment
AT rosenleitnerjan riskofptsdduetothecovid19pandemicamongpatientsinopioidsubstitutiontreatment